Iovance Biotherapeutics completed a preliminary analysis of the Phase II trial for its autologous tumour-infiltrating lymphocyte (TIL) therapy, Lifileucel (LN-145), in patients with metastatic non-small cell lung cancer (NSCLC) after a US Food and Drug Administration (FDA) review found the trial design may be suitable for accelerated approval.
The positive regulatory feedback was part of a Type B Pre-Phase III meeting and is based on Lifileucel’s use in patients with advanced and non-genomic mutated NSCLC who have received at least one line of an FDA-approved targeted therapy.
The Phase II trial for Lifileucel in metastatic NSCLC is planning an expected enrolment of 120 patients and a completion date in the second half of 2024. Iovance is also preparing to meet with the US FDA regarding a confirmatory trial of the autologous TIL in frontline advanced NSCLC patients.
Lifileucel received a biologics license application (BLA) in May 2023, with a Prescription Drug User Fee Act (PDUFA) target action date set for 25 November 2023.
GlobalData, the parent company of Pharmaceutical Technology, predicts Lifileucel to have global sales of $889m in 2029, with annual US sales reaching $281m in 2037.
Phase II preliminary data
A total of 23 patients were included in the data analysis from the open-label, non-randomised Phase II IOV-LUN-202 trial (NCT04614103) evaluating the safety and efficacy of Lifileucel in patients with metastatic anti-programmed cell death-ligand 1 (anti-PD-L1) NSCLC.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The overall response rate was 26.1%, with one patient achieving a complete response while the other five only showed partial response.
The disease control rate was 82.6%. The median duration of response was not reached and ranged from 1.4+ to 9.7+ months.
No unexpected adverse events due to Lifileucel were reported. However, those relating to the underlying disease, non-myeloablative lymphodepletion, and interleukin-2 were observed during the study.
Other secondary endpoints of the trial include disease control rate, progression-free survival, and overall survival.
Lifileucel is also being evaluated for other solid tumour indications.